Human induced pluripotent stem cells in regenerative medicine
Author: Uhlin, Elias
Date: 2019-11-22
Location: CMB Lecture Hall, Berzelius väg 21, Karolinska Institutet, Stockholm
Time: 09.30
Department: Inst för neurovetenskap / Dept of Neuroscience
View/ Open:
Thesis (1.572Mb)
Abstract
Human induced pluripotent (iPS) cells offer a theoretically inexhaustible cell source for the
derivation of any cell type and are a promising tool in regenerative medicine. Cells can be
derived from the recipients own tissue or from pre-selected HLA-matched donors. Certain
disease relevant cell types derived from iPS cells can be cryopreserved, distributed worldwide
and made available on demand. These factors taken together indicates iPS cells could
potentially revolutionize medicine.
Technological maturation has been fast paced with rapid advances in derivation and culture techniques in the last decade, creating cells of sufficient quality to motivate in human use. The first clinical trials performed with iPS cell derived grafts have so far been conducted without indications of adverse events. Pioneering applications are now being evaluated in humans. Meanwhile, academia and industry alike are taking strides to industrialize cell manufacture in anticipation of commercial applications. Strategies utilizing genome editing are opening up entirely new venues for future applications.
However, challenges does not solely lay in developing efficacious cell therapies. Pioneering cell therapy products have so far been exceptionally costly. Finding strategies minimize cost may be as an important as proving efficacy if any novel cell therapies are ever going to benefit society.
Regulations dictating the use of iPS cell derived cell therapies remains unspecific yet demanding and insufficiently harmonized internationally. Efforts are ongoing to coordinate in-between regulatory authorities and more defined criteria for manufacture and regulatory approval is slowly emerging.
It has now been little over 10 years since the derivation of the first human iPS cell lines. A decade which has seen many barriers overcome. The upcoming decade is likely to be even more exciting and challenging, as therapies will need, not only to be consistently proven safe, but also efficacious and commercially viable.
Technological maturation has been fast paced with rapid advances in derivation and culture techniques in the last decade, creating cells of sufficient quality to motivate in human use. The first clinical trials performed with iPS cell derived grafts have so far been conducted without indications of adverse events. Pioneering applications are now being evaluated in humans. Meanwhile, academia and industry alike are taking strides to industrialize cell manufacture in anticipation of commercial applications. Strategies utilizing genome editing are opening up entirely new venues for future applications.
However, challenges does not solely lay in developing efficacious cell therapies. Pioneering cell therapy products have so far been exceptionally costly. Finding strategies minimize cost may be as an important as proving efficacy if any novel cell therapies are ever going to benefit society.
Regulations dictating the use of iPS cell derived cell therapies remains unspecific yet demanding and insufficiently harmonized internationally. Efforts are ongoing to coordinate in-between regulatory authorities and more defined criteria for manufacture and regulatory approval is slowly emerging.
It has now been little over 10 years since the derivation of the first human iPS cell lines. A decade which has seen many barriers overcome. The upcoming decade is likely to be even more exciting and challenging, as therapies will need, not only to be consistently proven safe, but also efficacious and commercially viable.
List of papers:
I. Uhlin, E. Rönnholm, H. Day, K. Kele, M. Tammimies, K. Bölte, S. Falk, A. Derivation of Human iPS Cell Lines from Monozygotic Twins in Defined and Xeno Free Conditions. Stem Cell Research. doi.org/10.1016/j.scr.2016.12.006
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Uhlin, E. Marin Navarro, A. Rönnholm, H. Day, K. Kele. Falk, A. Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix. Journal of Visualized Experiments, 2017 Jul 7;(125).
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Uhlin, E. Kele, M. Rönnholm, H. Day, K. Ulfenborg, H. Anderlid, B. Falk, A. Derivation of a GMP-Compliant Human iPS Cell Line “KICRi001-A” from Dermal Fibroblasts by RNA-Mediated Reprogramming. [Submitted]
IV. Uhlin, E. Kele, M. Winblad, N. Baqué–Vidal, L. Petrus-Reurer, S. Bengtsson, M. Lanner, F. Falk, A. A Strategy for the Creation of a Clinical Grade iPS Cell Bank Covering a Majority of the World Population by CRISPR-Cas9 Genome Editing. [Manuscript]
V. Uhlin, E. Morse, R. Kele, M. Holmberg, L. Xu, L. Moslem, M. Sundström, E. Falk, A. Pre-Clinical Evaluation of Clinically Relevant iPS Cell Derived Neuroepithelial Stem Cells as an Off-the-Shelf Cell Therapy for Spinal Cord Injury. [Manuscript]
I. Uhlin, E. Rönnholm, H. Day, K. Kele, M. Tammimies, K. Bölte, S. Falk, A. Derivation of Human iPS Cell Lines from Monozygotic Twins in Defined and Xeno Free Conditions. Stem Cell Research. doi.org/10.1016/j.scr.2016.12.006
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. Uhlin, E. Marin Navarro, A. Rönnholm, H. Day, K. Kele. Falk, A. Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix. Journal of Visualized Experiments, 2017 Jul 7;(125).
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Uhlin, E. Kele, M. Rönnholm, H. Day, K. Ulfenborg, H. Anderlid, B. Falk, A. Derivation of a GMP-Compliant Human iPS Cell Line “KICRi001-A” from Dermal Fibroblasts by RNA-Mediated Reprogramming. [Submitted]
IV. Uhlin, E. Kele, M. Winblad, N. Baqué–Vidal, L. Petrus-Reurer, S. Bengtsson, M. Lanner, F. Falk, A. A Strategy for the Creation of a Clinical Grade iPS Cell Bank Covering a Majority of the World Population by CRISPR-Cas9 Genome Editing. [Manuscript]
V. Uhlin, E. Morse, R. Kele, M. Holmberg, L. Xu, L. Moslem, M. Sundström, E. Falk, A. Pre-Clinical Evaluation of Clinically Relevant iPS Cell Derived Neuroepithelial Stem Cells as an Off-the-Shelf Cell Therapy for Spinal Cord Injury. [Manuscript]
Institution: Karolinska Institutet
Supervisor: Falk, Anna
Co-supervisor: Kele, Malin
Issue date: 2019-10-29
Rights:
Publication year: 2019
ISBN: 978-91-7831-610-6
Statistics
Total Visits
Views | |
---|---|
Human ... | 395 |
Total Visits Per Month
September 2020 | October 2020 | November 2020 | December 2020 | January 2021 | February 2021 | March 2021 | |
---|---|---|---|---|---|---|---|
Human ... | 15 | 9 | 8 | 15 | 9 | 7 | 0 |
File Visits
Views | |
---|---|
Thesis_Elias_Uhlin.pdf | 690 |
Top country views
Views | |
---|---|
Sweden | 93 |
United States | 60 |
China | 46 |
Germany | 24 |
Netherlands | 16 |
Italy | 9 |
Russia | 9 |
Australia | 8 |
France | 6 |
United Kingdom | 6 |
Top cities views
Views | |
---|---|
Stockholm | 32 |
Ashburn | 28 |
Beijing | 10 |
Mountain View | 9 |
Shenzhen | 7 |
Dongguan | 5 |
St Petersburg | 5 |
Amsterdam | 4 |
Bratislava | 4 |
Pisa | 4 |